SG11201901389XA - Combination therapy with glutaminase inhibitors - Google Patents
Combination therapy with glutaminase inhibitorsInfo
- Publication number
- SG11201901389XA SG11201901389XA SG11201901389XA SG11201901389XA SG11201901389XA SG 11201901389X A SG11201901389X A SG 11201901389XA SG 11201901389X A SG11201901389X A SG 11201901389XA SG 11201901389X A SG11201901389X A SG 11201901389XA SG 11201901389X A SG11201901389X A SG 11201901389XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- glutaminase
- seaport
- california
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/039544 Al 01 March 2018 (01.03.2018) W I P0 I P C T (51) International Patent Classification: A61K 31/433 (2006.01) C07D 417/02 (2006.01) Declarations under Rule 4.17: A61K 31/501 (2006.01) CO7D 417/14 (2006.01) — of inventorship (Rule 4.17(iv)) A61P 35/00 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/US2017/048581 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of (22) International Filing Date: amendments (Rule 48.2(h)) 25 August 2017 (25.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/379,604 25 August 2016 (25.08.2016) US (71) Applicant: CALITHERA BIOSCIENCES, INC. [US/US]; 343 Oyster Point Boulevard, Suite 200, South San Francisco, California 94080 (US). (72) Inventors: PARLATI, Francesco; 1035 York Street, San _ Francisco, California 94110 (US). ORFORD, Keith; 3819 Charter Club Drive, Doylestown, Pennsylvania 18902 (US). — = WHITING, Sam, H.; 8920 Sand Point Way NE, Seattle, Washington 98115 (US). = Agent: HALSTEAD, David, P. et al.; Foley Hoag (74) — LLP, Seaport West, 155 Seaport Boulevard, Boston, MA _ = 02210-2600 (US). Designated States (unless otherwise indicated, for every = (81) — kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = = = = MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, — OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every = (84) = kind of regional protection available): ARIPO (BW, GH, = GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = — 1-1 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). 71' 71' kin tz . M © (54) Title: COMBINATION THERAPY WITH GLUTAMINASE INHIBITORS --.... ,1 (57) : The invention relates to methods of treating cancer or myeloproliferative diseaseswith a combination of a glutaminase 0 inhibitor and an anticancer agent selected from cabozantinib, crizotinib, and axitinib. The invention further relates to methods of treating N cancer or myeloproliferative diseases that are resistant to one or more anticancer agents.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662379604P | 2016-08-25 | 2016-08-25 | |
PCT/US2017/048581 WO2018039544A1 (en) | 2016-08-25 | 2017-08-25 | Combination therapy with glutaminase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201901389XA true SG11201901389XA (en) | 2019-03-28 |
Family
ID=61240223
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201901389XA SG11201901389XA (en) | 2016-08-25 | 2017-08-25 | Combination therapy with glutaminase inhibitors |
Country Status (12)
Country | Link |
---|---|
US (2) | US10278968B2 (en) |
EP (1) | EP3503886A4 (en) |
JP (1) | JP2019526560A (en) |
KR (1) | KR20190040302A (en) |
CN (1) | CN110139649A (en) |
AU (1) | AU2017315446A1 (en) |
BR (1) | BR112019003533A2 (en) |
CA (1) | CA3034890A1 (en) |
EA (1) | EA201990567A1 (en) |
MX (1) | MX2019002108A (en) |
SG (1) | SG11201901389XA (en) |
WO (1) | WO2018039544A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102220175B1 (en) | 2012-11-16 | 2021-02-24 | 칼리테라 바이오사이언시즈, 인코포레이티드 | Heterocyclic glutaminase inhibitors |
US10316030B2 (en) | 2014-08-07 | 2019-06-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
KR20170132333A (en) | 2015-04-06 | 2017-12-01 | 칼리테라 바이오사이언시즈, 인코포레이티드 | Treatment of lung cancer with glutaminase inhibitor |
WO2017062354A1 (en) | 2015-10-05 | 2017-04-13 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors and immuno-oncology agents |
EA201990567A1 (en) | 2016-08-25 | 2019-08-30 | Калитера Байосайенсиз, Инк. | COMBINED THERAPY WITH GLUTAMINASE INHIBITORS |
EP3503893A4 (en) | 2016-08-25 | 2020-04-29 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
US11590122B2 (en) | 2021-02-19 | 2023-02-28 | Slayback Pharma Llc | Pharmaceutical compositions of cabozantinib |
KR20230001587A (en) * | 2021-06-28 | 2023-01-05 | 연세대학교 산학협력단 | A pharmaceutical composition for preventing or treating cancer |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
US20040198716A1 (en) | 2001-02-05 | 2004-10-07 | Dorit Arad | Cysteine protease inhimbitors |
AU2005245785B2 (en) | 2004-04-15 | 2011-04-07 | Banyan Biomarkers Inc. | Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining |
KR101325374B1 (en) | 2008-02-19 | 2013-11-08 | 가부시키가이샤 오츠까 세이야꾸 고죠 | Oral or enteral composition useful for recovery of physical functions |
US20130109643A1 (en) | 2010-05-10 | 2013-05-02 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
AU2011329619A1 (en) | 2010-11-18 | 2013-05-02 | Deuteria Pharmaceuticals, Inc. | 3-deutero-pomalidomide |
CN103030597B (en) | 2011-09-30 | 2014-10-01 | 南昌滨西科技有限公司 | Kidney type glutaminase inhibitor as well as preparation method and application kidney type glutaminase inhibitor |
BR112014012129A8 (en) | 2011-11-21 | 2017-06-20 | Calithera Biosciences Inc | heterocyclic glutaminase inhibitors |
US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
BR112015005243A2 (en) | 2012-09-10 | 2017-07-04 | Celgene Corp | Methods For Treating Locally Advanced Breast Cancer |
KR102220175B1 (en) | 2012-11-16 | 2021-02-24 | 칼리테라 바이오사이언시즈, 인코포레이티드 | Heterocyclic glutaminase inhibitors |
ES2761951T3 (en) | 2012-11-21 | 2020-05-21 | Agios Pharmaceuticals Inc | Glutaminase inhibitors and methods of use |
US9029531B2 (en) * | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
CN105283182A (en) | 2012-12-03 | 2016-01-27 | 卡利泰拉生物科技公司 | Treatment of cancer with heterocyclic inhibitors of glutaminase |
WO2015061432A1 (en) | 2013-10-25 | 2015-04-30 | Calithera Biosciences, Inc. | Treatment of viral infections with inhibitors of glutaminase |
EA201690746A1 (en) | 2013-10-25 | 2016-12-30 | Фармасайкликс Элэлси | TREATMENT WITH THE USE OF BLUTON AND IMMUNOTHERAPY THYROZINKINASE INHIBITORS |
US20150258082A1 (en) | 2014-03-14 | 2015-09-17 | Francesco Parlati | Combination therapy with glutaminase inhibitors |
US10221459B2 (en) | 2014-05-13 | 2019-03-05 | Case Western Reserve University | Compositions and methods of treating cancer harboring PIKC3A mutations |
BR112016029041A8 (en) * | 2014-06-13 | 2021-07-20 | Calithera Biosciences Inc | use of a glutaminase inhibitor, pharmaceutical composition and pharmaceutical kit |
WO2016004418A1 (en) * | 2014-07-03 | 2016-01-07 | Board Of Regents, University Of Texas System | Glutaminase inhibitor therapy |
WO2016014890A1 (en) | 2014-07-24 | 2016-01-28 | Calithera Biosciences, Inc. | Treatment of multiple myeloma with heterocyclic inhibitors of glutaminase |
US10316030B2 (en) | 2014-08-07 | 2019-06-11 | Calithera Biosciences, Inc. | Crystal forms of glutaminase inhibitors |
WO2016054388A1 (en) | 2014-10-03 | 2016-04-07 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Glutaminase inhibitors |
WO2016077632A2 (en) * | 2014-11-13 | 2016-05-19 | Buck Institute For Research On Aging | Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications |
MX2017012408A (en) | 2015-03-30 | 2018-04-26 | Calithera Biosciences Inc | Methods of administering glutaminase inhibitors. |
KR20170132333A (en) | 2015-04-06 | 2017-12-01 | 칼리테라 바이오사이언시즈, 인코포레이티드 | Treatment of lung cancer with glutaminase inhibitor |
EA201990567A1 (en) | 2016-08-25 | 2019-08-30 | Калитера Байосайенсиз, Инк. | COMBINED THERAPY WITH GLUTAMINASE INHIBITORS |
EP3503893A4 (en) | 2016-08-25 | 2020-04-29 | Calithera Biosciences, Inc. | Combination therapy with glutaminase inhibitors |
US20180055825A1 (en) | 2016-08-25 | 2018-03-01 | Yu Liang | Treatment of cancer with inhibitors of glutaminase |
-
2017
- 2017-08-25 EA EA201990567A patent/EA201990567A1/en unknown
- 2017-08-25 EP EP17844477.4A patent/EP3503886A4/en not_active Withdrawn
- 2017-08-25 SG SG11201901389XA patent/SG11201901389XA/en unknown
- 2017-08-25 MX MX2019002108A patent/MX2019002108A/en unknown
- 2017-08-25 AU AU2017315446A patent/AU2017315446A1/en not_active Abandoned
- 2017-08-25 WO PCT/US2017/048581 patent/WO2018039544A1/en unknown
- 2017-08-25 CN CN201780065628.1A patent/CN110139649A/en active Pending
- 2017-08-25 US US15/686,403 patent/US10278968B2/en not_active Expired - Fee Related
- 2017-08-25 BR BR112019003533-8A patent/BR112019003533A2/en not_active Application Discontinuation
- 2017-08-25 KR KR1020197008262A patent/KR20190040302A/en not_active Application Discontinuation
- 2017-08-25 JP JP2019510659A patent/JP2019526560A/en active Pending
- 2017-08-25 CA CA3034890A patent/CA3034890A1/en not_active Abandoned
-
2019
- 2019-03-14 US US16/353,516 patent/US20190275038A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20180055843A1 (en) | 2018-03-01 |
EA201990567A1 (en) | 2019-08-30 |
EP3503886A1 (en) | 2019-07-03 |
EP3503886A4 (en) | 2020-07-22 |
CA3034890A1 (en) | 2018-03-01 |
MX2019002108A (en) | 2019-07-08 |
AU2017315446A1 (en) | 2019-03-07 |
BR112019003533A2 (en) | 2019-05-21 |
US20190275038A1 (en) | 2019-09-12 |
CN110139649A (en) | 2019-08-16 |
WO2018039544A1 (en) | 2018-03-01 |
US10278968B2 (en) | 2019-05-07 |
JP2019526560A (en) | 2019-09-19 |
KR20190040302A (en) | 2019-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201901389XA (en) | Combination therapy with glutaminase inhibitors | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201909949XA (en) | Targeted immunotolerance | |
SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
SG11201901126UA (en) | Combination therapy for cancer | |
SG11201810034XA (en) | ANTI-cMet ANTIBODY DRUG CONJUGATES AND METHODS FOR THEIR USE | |
SG11201908391XA (en) | Methods for modulating an immune response | |
SG11201900344YA (en) | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
SG11201900163PA (en) | Macrocycle kinase inhibitors | |
SG11201804263PA (en) | Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor | |
SG11201804384UA (en) | Geometric configurations for gastric residence systems | |
SG11201803906PA (en) | Control of cellular redox levels | |
SG11201908786VA (en) | Substituted indoline derivatives as dengue viral replication inhibitors | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
SG11201909064RA (en) | Combination of an anti-pd-l1 antibody and a dna-pk inhibitor for the treatment of cancer | |
SG11201810454YA (en) | Use of an anti-pd-1 antibody in combination with an anti-cd30 antibody in lymphoma treatment | |
SG11201810196RA (en) | Cancer treatments |